Imugene Limited (ASX: IMU)
Health Care · Biotechnology · AU
AU$0.04
-2.56% today · -90.8% 1Y
Imugene Limited (ASX: IMU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.09M and employs 14 people.
Over the last twelve months the share price has lost 90.8%, trading between 0.03 and 0.43.
Tweenvest scores Imugene Limited across four factors: quality 24/100, value 40/100. Its strongest factor is value.
IMU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.09M
- Revenue (TTM)
- $1.44M
- P/E
- —
- EPS
- -0.32
- Dividend yield
- —
- Beta (5Y)
- 2.24
- 52-week high
- AU$0.43
- 52-week low
- AU$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 489.72M
- Employees
- 14
- Next earnings
- —
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
- ISIN
- AU000000IMU9
- Listed since
- Dec 30, 1993
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biophytis S.A.ENXTPA: ALBPS | $13.57M | €0.03 | +8.81% |
| Genflow Biosciences plcLSE: GENF | $13.22M | £0.02 | -1.41% |
| Alzinova AB (publ)OM: ALZ | $13.21M | Skr0.43 | -1.96% |
| Genomed Spólka AkcyjnaWSE: GEN | $13.14M | zł38.60 | -3.50% |
| TME Pharma N.V.ENXTPA: ALTME | $13.07M | €0.12 | +12.32% |
| Genomtec S.A.WSE: GMT | $12.72M | zł2.90 | -5.70% |
| Algorae Pharmaceuticals LimitedASX: 1AI | $12.70M | AU$0.01 | +12.50% |
| America Great HealthOTCPK: AAGH | $12.69M | $0.00 | +100.00% |
Figures last refreshed Oct 18, 2026.